Etiological treatment during early chronic indeterminate Chagas disease incites an activated status on innate and adaptive immunity associated with a type 1-modulated cytokine pattern

Microbes and Infection

Volumn 10, Issue 2, 2008, Pages 103-113

  Sathler Avelar, Renato ^a,b   Vitelli Avelar, Danielle Marquete ^a   Massara, Rodrigo Lima ^a   de Lana, Marta ^c   Pinto Dias, João Carlos ^a   Teixeira Carvalho, Andréa ^a   Elói Santos, Silvana Maria ^a,b   Martins Filho, Olindo Assis ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

Author keywords

Benznidazole; Chagas disease; Cytokines; Immune response; Leukocytes subsets

Indexed keywords

BENZNIDAZOLE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CD14 ANTIGEN; CD16 ANTIGEN; CD3 ANTIGEN; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 12;

ADAPTIVE IMMUNITY; ADOLESCENT; ARTICLE; B LYMPHOCYTE ACTIVATION; CHAGAS DISEASE; CHILD; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOREGULATION; INNATE IMMUNITY; LEUKOCYTE ACTIVATION; LONGITUDINAL STUDY; NATURAL KILLER CELL; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRYPANOSOMA CRUZI;

ADOLESCENT; ANTIGENS, CD; ANTIPROTOZOAL AGENTS; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CHAGAS DISEASE; CHILD; CYTOKINES; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; LONGITUDINAL STUDIES; LYMPHOCYTE ACTIVATION; MONOCYTES; NITROIMIDAZOLES; T-LYMPHOCYTES;

EID: 39749202944     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2007.10.009     Document Type: Article

References (27)

1. WHO. Expert Committee, control of Chagas disease. World Health Organ Tech. Rep. 905 (2002) 1-109
2. de Andrade A.L., Zicker F., de Oliveira R.M., Almeida Silva S., Luquetti A., Travassos L.R., Almeida I.C., de Andrade S.S., de Andrade J.G., and Martelli C.M. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 343 (1996) 1407-1413
3. Secretaria de Vigilância em Saúde do Ministério da Saúde, Consenso brasileiro em doença de Chagas. Revista Soc Bras Med Trop 38 (2005) 1-29
4. Viotti R., Vigliano C., Armenti H., and Segura E. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am. Heart J. 127 (1994) 51-62
5. Garcia S., Ramos C.O., Senra J.F., Vilas-Boas F., Rodrigues M.M., Campos-de-Carvalho A.C., Ribeiro-Dos-Santos R., and Soares M.B. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob. Agents Chemother. 49 (2005) 1521-1528
6. Rassi A., and Rassi Jr. A. Treatment of chronic Chagas' disease. Is the etiological treatment effective?. Arq. Bras. Cardiol. 71 (1998) 643-646
7. Sosa Estani S., Segura E.L., Ruiz A.M., Velazquez E., Porcel B.M., and Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am. J. Trop. Med. Hyg. 59 (1998) 526-529
8. Andrade S.G., Freitas L.A., Peyrol S., Pimentel A.R., and Sadigursky M. Experimental chemotherapy of Trypanosoma cruzi infection: persistence of parasite antigens and positive serology in parasitologically cured mice. Bull. World Health Organ. 69 (1991) 191-197
9. Bahia-Oliveira L.M., Gomes J.A., Cançado J.R., Ferrari T.C., Lemos E.M., Luz Z.M., Moreira M.C., Gazzinelli G., and Correa-Oliveira R. Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14-30 years ago. J. Infect. Dis. 182 (2000) 634-638
10. Gomes J.A., Bahia-Oliveira L.M., Rocha M.O., Martins-Filho O.A., Gazzinelli G., and Correa-Oliveira R. Evidence that development of severe cardiomyopathy in human Chagas' disease is due to a Th1-specific immune response. Infect. Immun. 71 (2003) 1185-1193
11. Sathler-Avelar R., Vitelli-Avelar D.M., Massara R.L., Borges J.D., Lana M., Teixeira-Carvalho A., Dias J.C., Eloi-Santos S.M., and Martins-Filho O.A. Benznidazole treatment during early-indeterminate Chagas' disease shifted the cytokine expression by innate and adaptive immunity cells toward a type 1-modulated immune profile. Scand. J. Immunol. 64 (2006) 554-563
12. Olivieri B.P., Cotta-De-Almeida V., and Araujo-Jorge T. Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+T-cell expansion and promotes resistance to reinfection. Antimicrob. Agents Chemother. 46 (2002) 3790-3796
13. +T cells, the key to control Chagas' disease morbidity?. Clin. Exp. Immunol. 145 (2006) 81-92
14. Dutra W.O., Martins-Filho O.A., Cancado J.R., Pinto-Dias J.C., Brener Z., Freeman Jr. G.L., Colley D.G., Gazzinelli G., and Parra J.C. Activated T and B lymphocytes in peripheral blood of patients with Chagas' disease. Int. Immunol. 6 (1994) 499-506
15. Dutra W.O., da Luz Z.M., Cançado J.R., Pereira M.E., Brigido-Nunes R.M., Galvão L.M., Colley D.G., Brener Z., Gazzinelli G., and Carvalho-Parra J.F. Influence of parasite presence on the immunologic profile of peripheral blood mononuclear cells from chagasic patients after specific drug therapy. Parasite Immunol. 18 (1996) 579-585
16. High regulatory T lymphocytes. Scand. J. Immunol. 62 (2005) 297-308
17. Sathler-Avelar R., Lemos E.M., Reis D.D., Medrano-Mercado N., Araujo-Jorge T.C., Antas P.R., Correa-Oliveira R., Teixeira-Carvalho A., Eloi-Santos S.M., Favato D., and Martins-Filho O.A. Phenotypic features of peripheral blood leukocytes during early stages of human infection with Trypanosoma cruzi. Scand. J. Immunol. 58 (2003) 655-663
18. Laffon A., Garcia-Vicuna R., Humbria A., Postigo A.A., Corbi A.L., de Landazuri M.O., and Sanchez-Madrid F. Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis. J. Clin. Invest. 88 (1991) 546-552
19. Sancho D., Gomez M., and Sanchez-Madrid F. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol. 26 (2005) 136-140
20. Gontijo E.D., Galvão L.M., and Eloi-Santos S. Chagas disease: criteria of cure and prognosis. Mem. Inst. Oswaldo Cruz 94 (1999) 357-362
21. Pascutti M.F., Pitashny M., Nocito A.L., Guermonprez P., Amigorena S., Wietzerbin J., Serra E., Bottasso O., and Revelli S. Benznidazole, a drug used in Chagas' disease, ameliorates LPS-induced inflammatory response in mice. Life Sci. 76 (2004) 685-697
22. Rodriques Coura J., and de Castro S.L. A critical review on Chagas disease chemotherapy. Mem. Inst. Oswaldo Cruz 97 (2002) 3-24
23. Urbina J.A. Chemotherapy of Chagas' disease: the how and the why. J. Mol. Med. 77 (1999) 332-338
24. Michailowsky V., Murta S.M., Carvalho-Oliveira L., Pereira M.E., Ferreira L.R., Brener Z., Romanha A.J., and Gazzinelli R.T. Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of Trypanosoma cruzi. Antimicrob. Agents Chemother. 42 (1998) 2549-2556
25. Belge K.U., Dayyani F., Horelt A., Siedlar M., Frankenberger M., Frankenberger B., Espevik T., and Ziegler-Heitbrock L. The pro-inflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J. Immunol. 168 (2002) 3536-3542
26. + subpopulation. Immunol. Today 17 (1996) 424-428
27. Brener Z., and Gazzinelli R.T. Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease. Int. Arch. Allergy Immunol. 114 (1997) 103-110